Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.

de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A; Madrid cohort of HIV-infected children..

J Antimicrob Chemother. 2011 Oct;66(10):2362-71. doi: 10.1093/jac/dkr305.

PMID:
21810838
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.
4.

Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.

Rojas Sánchez P, Holguín A.

J Antimicrob Chemother. 2014 Aug;69(8):2032-42. doi: 10.1093/jac/dku104. Review.

PMID:
24788658
5.

The development of anti-HIV-1 drugs.

Lu XF, Chen ZW.

Yao Xue Xue Bao. 2010 Feb;45(2):165-76. Review.

PMID:
21348415
6.
7.

Targeting HIV: antiretroviral therapy and development of drug resistance.

Menéndez-Arias L.

Trends Pharmacol Sci. 2002 Aug;23(8):381-8. Review.

PMID:
12377580
8.

HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF.

Lancet Infect Dis. 2011 Oct;11(10):769-79. doi: 10.1016/S1473-3099(11)70141-4. Review.

PMID:
21872531
9.

Resistance and cross-resistance to abacavir.

Moyle G.

HIV Med. 2001 Jul;2(3):154-62. Review.

10.

Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Fraaij PL, van Kampen JJ, Burger DM, de Groot R.

Clin Pharmacokinet. 2005;44(9):935-56. Review.

PMID:
16122281
11.

Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996-2010.

Pant Pai N, Shivkumar S, Cajas JM.

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):382-8. doi: 10.1097/QAI.0b013e31824a0628. Review.

PMID:
22269800
12.

Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.

Sierra-Aragón S, Walter H.

Intervirology. 2012;55(2):84-97. doi: 10.1159/000331995. Review.

PMID:
22286875
13.

Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Lie Y, Coakley E, Hammer SM, Brudney K.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):667-74. doi: 10.1089/AID.2010.0355. Review.

14.

The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.

Sendagire H, Easterbrook PJ, Nankya I, Arts E, Thomas D, Reynolds SJ.

AIDS Rev. 2009 Apr-Jun;11(2):59-70. Review.

15.
16.

[Epidemiology of drug-resistant HIV-1 transmission in naïve patients in Spain].

Yebra G, Holguín A.

Med Clin (Barc). 2010 Oct 16;135(12):561-7. doi: 10.1016/j.medcli.2009.09.029. Review. Spanish.

PMID:
19959197
17.

[Relevance of HIV resistance testing for treatment decisions].

Mor O, Grossman Z, Avidor B, Turner D.

Harefuah. 2013 Apr;152(4):230-4, 245-6. Review. Hebrew.

PMID:
23844526
18.

Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development.

Emamzadeh-Fard S, Esmaeeli S, Arefi K, Moradbeigi M, Heidari B, Fard SE, Paydary K, Seyedalinaghi S.

Infect Disord Drug Targets. 2013 Oct;13(5):330-6. Review.

PMID:
24712673
19.

Special aspects of the treatment of HIV-2-infected patients.

Camacho RJ.

Intervirology. 2012;55(2):179-83. doi: 10.1159/000332025. Review.

PMID:
22286890
20.

[Evolution and Diversity of HIV-1].

Metzner KJ.

Praxis (Bern 1994). 2011 Jan 5;100(1):29-35. doi: 10.1024/1661-8157/a000403. Review. German.

PMID:
21210358

Supplemental Content

Support Center